Top Page
PainChek Ltd
(Sydney:PCK)
PainChek Ltd (PCK) vs. iShares MSCI Australia ETF (EWA)
PainChek Ltd Business Overview & Revenue Model
PainChek Ltd Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.59M | 3.36M | 2.67M | 1.95M | 978.57K | 214.80K |
| Gross Profit | 733.87K | 997.74K | 726.66K | 712.51K | -258.82K | -424.21K |
| EBITDA | -6.98M | -7.65M | -9.49M | -8.61M | -6.80M | -7.06M |
| Net Income | -6.96M | -7.67M | -8.31M | -7.57M | -5.72M | -6.06M |
Balance Sheet | ||||||
| Total Assets | 5.54M | 2.15M | 4.18M | 2.80M | 6.65M | 11.81M |
| Cash, Cash Equivalents and Short-Term Investments | 4.78M | 1.62M | 3.56M | 2.51M | 6.14M | 11.42M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 3.04M | 3.26M | 2.89M | 2.13M | 1.83M | 3.57M |
| Stockholders Equity | 2.49M | -1.11M | 1.29M | 668.13K | 4.82M | 8.24M |
Cash Flow | ||||||
| Free Cash Flow | -6.03M | -6.77M | -7.16M | -6.34M | -7.02M | -4.18M |
| Operating Cash Flow | -6.01M | -6.75M | -7.13M | -6.32M | -7.00M | -4.12M |
| Investing Cash Flow | -17.57K | -12.17K | -34.25K | -12.44K | -21.96K | -60.03K |
| Financing Cash Flow | 9.00M | 4.82M | 8.21M | 2.70M | 1.75M | 9.48M |
PainChek Ltd Technical Analysis
PainChek Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | AU$131.61M | 26.51 | 1.89% | ― | 10.06% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$76.38M | -6.28 | -12.35% | ― | 15.99% | 22.05% | |
47 Neutral | AU$18.13M | 3.95 | -17.05% | ― | 28.91% | -1050.00% | |
45 Neutral | AU$35.53M | -3.13 | -8647.54% | ― | 25.98% | 22.10% | |
44 Neutral | AU$45.05M | -5.70 | -13.83% | ― | 3.61% | -17.03% |
PainChek Ltd Corporate Events
PainChek Ltd has announced the cessation of a tranche of listed options, with 16,653,867 PCKAZ options expiring unexercised on 3 March 2026. The lapse of these options slightly simplifies the company’s capital structure but does not raise new capital, implying no immediate dilution or cash inflow impact for existing shareholders.
The notification formalises the removal of these options from the company’s issued securities on the ASX and reflects standard lifecycle management of expiring convertible instruments. While operational activities are unaffected, the change may modestly alter future potential equity overhang and is relevant for investors tracking PainChek’s fully diluted capital base.
The most recent analyst rating on (AU:PCK) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.
PainChek Limited reported half-year revenue from continuing operations of $1.73 million for the six months to 31 December 2025, up 5% year on year, but total revenue fell 42% to $1.76 million due to a sharp reduction in grant income. The company’s net loss attributable to members widened by 42% to $4.70 million, net tangible assets per share eased to 1.2 cents from 1.3 cents, no dividends were declared, and its auditor highlighted a going concern emphasis of matter, underscoring ongoing financial pressures and funding risks for shareholders.
The results indicate that while core operating revenue is growing modestly, PainChek remains reliant on external funding and faces profitability and balance sheet challenges. The going concern emphasis may affect investor sentiment and underscores the importance of future capital management and execution of its growth strategy to stabilise its financial position in a competitive health technology market.
The most recent analyst rating on (AU:PCK) stock is a Hold with a A$0.17 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.
PainChek Ltd has issued a total of 325,000 unquoted options under its employee incentive scheme, with exercise prices of $0.04 and $0.0356 and expiries in March and February 2030 respectively. The move underscores the company’s use of long-dated equity incentives to align staff interests with shareholders and support retention as it executes its growth and product commercialisation strategy.
The new options, which are not intended to be quoted on the ASX, expand PainChek’s pool of employee equity and may contribute to future dilution if exercised. For stakeholders, this structure signals continued investment in human capital while preserving cash, a common approach among growth-stage healthtech firms seeking to balance funding constraints with the need to attract and retain specialised talent.
The most recent analyst rating on (AU:PCK) stock is a Sell with a A$0.20 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.
PainChek has secured an independent US legal opinion confirming its AI-driven PainChek device qualifies as an FDA-regulated medical device for Remote Therapeutic Monitoring reimbursement, enabling US healthcare professionals to use it when submitting claims to the Centers for Medicare & Medicaid Services. Building on its FDA De Novo classification and unique ability to assess pain in non-verbal dementia patients with musculoskeletal conditions, the company can now participate in the rapidly expanding RTM market, projected to be worth billions of dollars annually, and is adding an RTM reimbursement-based model to its existing SaaS offering to long-term care facilities. This dual-revenue approach, combined with long-dated US patent protection and partnerships covering more than 25,000 long-term care facilities and providers, materially strengthens PainChek’s growth prospects and competitive position in the US pain management and remote monitoring market.
The most recent analyst rating on (AU:PCK) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.
PainChek Ltd, a global medtech company specialising in AI-driven pain assessment tools delivered via smartphones and tablets, has established a strong presence in aged care and related sectors, with regulatory approvals in multiple major markets and adoption in thousands of facilities worldwide. The company has announced it will host an investor webinar on 30 January 2026, following the release of its quarterly update and cash flow report, giving shareholders and investors an opportunity to hear the latest presentation from the CEO and ask questions, signalling continued engagement with the market as it advances the rollout and commercialisation of its pain assessment technology across clinical and home care settings.
The most recent analyst rating on (AU:PCK) stock is a Hold with a A$0.26 price target. To see the full list of analyst forecasts on PainChek Ltd stock, see the AU:PCK Stock Forecast page.
PainChek Limited has disclosed a change in the interests of director John Murray, who has allowed 40,000 options held indirectly through Nanjop Pty Ltd as trustee for the Murring Family Trust to lapse, resulting in no remaining options and no change to his total shareholding in the company. Following the lapse, Murray continues to hold 1,463,860 fully paid ordinary shares indirectly and 390,600 fully paid ordinary shares directly, a development that slightly alters the structure of his equity exposure by removing option-based incentives but leaves his direct and indirect share ownership unchanged, with no on-market trades reported and no closed-period trading issues raised.
PainChek Ltd has announced the expiry and cessation of 15,686,749 listed options (ASX code PCKAY) that carried an exercise price of A$0.50 and were due to expire on 19 December 2025, with the options lapsing unexercised. The expiry slightly simplifies the company’s capital structure by removing a large block of out-of-the-money options from its issued securities, which may clarify the potential future dilution profile for existing shareholders but does not immediately affect PainChek’s current cash position or operations.
PainChek Ltd has applied to the ASX for quotation of 24,775 new fully paid ordinary shares following the exercise or conversion of existing options or other convertible securities, with an issue date of 23 December 2025. The relatively small share issuance modestly increases the company’s quoted capital base and reflects ongoing conversion of incentive or financing-related instruments, with limited immediate impact on its overall capital structure but indicating continued engagement from holders of convertible securities.
PainChek Ltd has issued 176,471 fully paid ordinary shares to directors under a previously announced placement to sophisticated, professional and other exempt investors, following shareholder approval at its 2025 Annual General Meeting. The company has confirmed that the shares were issued without a prospectus under the Corporations Act exemption, that it is up to date with its financial reporting and continuous disclosure obligations, and that there is no undisclosed price-sensitive information, providing assurance to the market and existing shareholders about regulatory compliance and transparency around the capital raising.
PainChek Limited has disclosed a change in the holdings of its managing director, Philip Daffas, who has increased his direct stake in the company through the issue of 147,059 fully paid ordinary shares, taking his total shareholding to 3,114,226 shares alongside existing options and performance rights. The new shares were issued as part of a placement previously approved by shareholders at the 2025 Annual General Meeting, signalling continued alignment between executive leadership and shareholders’ interests and underscoring board-level participation in the company’s capital-raising activities.
PainChek Ltd has applied to the ASX for quotation of 176,471 new fully paid ordinary shares, issued on 22 December 2025 under a previously announced transaction. The modest share issuance expands the company’s quoted capital base and reflects ongoing use of equity to support its corporate or transactional activities, with limited immediate dilution but signalling continued capital management as PainChek advances its digital health technology in the market.
PainChek Ltd has announced the quotation of new securities on the Australian Securities Exchange (ASX), with a total of 339 ordinary fully paid securities to be issued. This move is part of the company’s strategy to enhance its financial position and potentially expand its market presence, impacting its operations and offering potential benefits to stakeholders.